Analytical Data
-
基因名
CD82
- Application
-
别名
CD82；KAI1；SAR2；ST6；CD82 antigen
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P27701
-
表达区间
1-267aa
-
氨基酸序列
MGSACIKVTKYFLFLFNLIFFILGAVILGFGVWILADKSSFISVLQTSSS SLRMGAYVFIGVGAVTMLMGFLGCIGAVNEVRCLLGLYFAFLLLILIAQV TAGALFYFNMGKLKQEMGGIVTELIRDYNSSREDSLQDAWDYVQAQVKCC GWVSFYNWTDNAELMNRPEVTYPCSCEVKGEEDNSLSVRKGFCEAPGNRT QSGNHPEDWPVYQEGCMEKVQAWLQENLGIILGVGVGVAIVELLGMVLSI CLCRHVHSEDYSKVPKY
-
分子量
55 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant E.coli tsaE Protein，His
Cat：PA2000-2820
Recombinant Human CCDC68 Protein，GST
Cat：PA2000-6514
Protein Description
CD82, also known as the KI-1 antigen, is a member of the tetraspanin family of proteins and plays a crucial role in cell adhesion, migration, and immune response regulation. It is widely expressed in various immune cells, including T cells, B cells, and antigen-presenting cells, suggesting its significance in modulating immune functions. Research indicates that CD82 is involved in tumor progression and metastasis, serving both as a suppressor and promoter in different cancer types, which makes it an intriguing target for therapeutic interventions. Additionally, the expression levels of CD82 have been correlated with clinical outcomes in several cancers, further highlighting its potential as a biomarker for cancer prognosis. Recent studies have explored the use of CD82 recombinant proteins in immunotherapy, aiming to leverage its capacity to enhance immune responses against tumors. By better understanding the biological functions and mechanisms of CD82, researchers hope to develop novel strategies that could improve cancer treatment outcomes and provide insights for the development of immunotherapeutic agents. The advancement of recombinant technology has facilitated the production of CD82 proteins, allowing for in-depth investigations into its structural characteristics and functional capabilities. Consequently, the ongoing research on CD82 recombinant proteins not only enhances our understanding of immune modulation but also paves the way for potential clinical applications in cancer therapy and beyond.
